Last reviewed · How we verify
Afrezza Inhalant Product
Afrezza Inhalant Product, marketed by Model Clinical Research LLC, is a unique inhaled insulin therapy currently available in the market. Its key strength lies in its mechanism of action, offering patients a non-injectable alternative for managing diabetes. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Afrezza Inhalant Product |
|---|---|
| Also known as | Afrezza Inhaled Insulin |
| Sponsor | Model Clinical Research LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients (PHASE3)
- A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |